Unlocking the potential of the microbiome is at the core of Second Genome's drug discovery efforts. Our research and development is focused on applying microbiome science to host biology to discover and develop more effective therapeutic options for patients. 


Second Genome Pipeline



Our lead candidate, SGM-1019, is a small molecule inhibitor targeting tissue injury and inflammation through inhibition of an inflammasome activation pathway identified using Second Genome’s microbiome drug discovery platform. This biology plays a key role in driving progression of NASH as well as IBD. SGM-1019 has completed both a single and multiple ascending oral dose trial in healthy subject. SGM-1019 achieved target exposure levels and was well tolerated. In addition, SGM-1019 demonstrated efficacy in preclinical models.

Second Genome is currently developing regulatory and clinical plans to enter phase 2 in 2018 as a first-in-class oral therapeutic candidate for the treatment of nonalcoholic steatohepatitis (NASH).


Inflammatory bowel disease (IBD) is a diverse disease of unknown etiology resulting in more frequent and bloody bowel movements accompanied with histopathological damage to the gastrointestinal mucosa.  While specific triggers of disease remain poorly defined, one proposal of disease progression suggests a breakdown of intestinal barrier function allows bacteria or bacterial components to translocate into mucosal tissue.  Bacterial translocation results in activation of inflammatory signaling which triggers additional barrier disruption, resulting in a cyclic amplification loop of barrier disruption, bacterial translocation and inflammation.  While many current therapies target inflammation, the lack of therapies promoting mucosal healing provides an opportunity for novel therapies promoting epithelial repair and intestinal barrier integrity.
SG-2-0776 is a novel therapeutic protein derived from the microbiome that restores damage caused to the intestinal epithelium, thereby promoting mucosal healing.